Does low thyroid hormone activity raise LDL cholesterol by reducing LDL particle clearance?

Overview

The physiological link between thyroid function and cholesterol metabolism is well-established, and the claim that low thyroid hormone activity can raise LDL cholesterol by reducing LDL particle clearance is strongly supported by biochemical, molecular, and clinical evidence.

Clinical and Physiological Evidence

• Impact on LDL Cholesterol (LDL-C) Levels: Clinical hypothyroidism is classically characterized by elevated serum total cholesterol and LDL-C levels. Even subclinical hypothyroidism (elevated TSH with normal free thyroid hormone levels) is associated with mild to moderate elevations in circulating LDL-C.
• Direct Impact on Clearance Rates: Kinetic studies in humans and animals show that the elevation of circulating LDL-C in hypothyroid states is primarily due to a decreased fractional catabolic rate (FCR) of LDL particles rather than an overproduction of lipoproteins. This means the body is cleared of LDL at a significantly slower rate.
• Reversibility: Treatment of thyroid hormone deficiency (e.g., with levothyroxine) restores thyroid hormone levels, upregulates LDL receptor (LDLR) expression, normalizes the fractional catabolic rate of LDL, and significantly reduces serum LDL-C levels.

Molecular Mechanisms

• Transcriptional Regulation of LDLR: Active thyroid hormone (triiodothyronine, or T3) binds to nuclear thyroid hormone receptors (TRs, primarily TRβ), which interact directly with thyroid hormone-responsive elements (TREs) in the promoter region of the LDLR gene, stimulating its transcription and increasing the abundance of LDL receptors on the surface of hepatocytes.
• SREBP-2 Pathway Activation: T3 also indirectly upregulates LDLR expression by enhancing the transcription and activation of Sterol Regulatory Element-Binding Protein 2 (SREBP-2), a master transcription factor that binds to the sterol response element (SRE) on the LDLR gene to drive its expression.
• PCSK9 Modulation: T3 negatively regulates the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9). Under normal thyroid conditions, lower PCSK9 levels prevent the lysosomal degradation of LDLR, allowing more receptors to recycle to the hepatocyte membrane. In low thyroid states, elevated PCSK9 levels increase LDLR degradation, further limiting LDL clearance.
• Alternative Clearance Pathways: Low thyroid activity also downregulates the expression of LDL receptor-related protein 1 (LRP1), which impairs the hepatic clearance of atherogenic remnant lipoproteins (apolipoprotein E-rich particles) in addition to LDL.

Bottom Line

Low thyroid hormone activity downregulates hepatic LDL receptor expression through both direct transcriptional regulation and auxiliary pathways (SREBP-2 and PCSK9). This reduction in active receptors impairs the liver's ability to clear LDL particles from the bloodstream, leading to a decreased fractional catabolic rate of LDL and a resulting increase in circulating serum LDL cholesterol.